Lazard Asset Management
LNAI

Lazard Asset Management’s Lunai Bioworks LNAI Stock Holding History

Lazard Asset Management’s Portfolio LNAI Stock Details LNAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed – – 2421
2024
Q2 		$0 Sell
1
-30
-97% -$4.09K ﹤0.01% 2392
2024
Q1 		$6K Sell
31
-18
-37% -$4.86K ﹤0.01% 1893
2023
Q4 		$12K Buy
+49
New +$13.4K ﹤0.01% 2088

Other funds holding LNAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Lazard Asset Management's LNAI Position: Q3 2024 in Review

Lazard Asset Management sold out of Lunai Bioworks (LNAI) in Q3 2024, closing a stake of 1 share.

Lazard Asset Management first reported a position in LNAI in Q4 2023 and held it in 3 quarters. The position peaked at $12K in Q4 2023. 49 funds tracked by Wall St. Rank hold LNAI as of Q3 2024.

  • Lazard Asset Management reported no remaining Lunai Bioworks position as of Q3 2024 after selling out during the quarter.
  • Lazard Asset Management sold 1 Lunai Bioworks share in Q3 2024.
  • Lazard Asset Management first reported a position in Lunai Bioworks in Q4 2023 and held it in 3 quarters.
  • Lazard Asset Management's Lunai Bioworks position peaked at $12K in Q4 2023.
  • 49 funds tracked by Wall St. Rank held Lunai Bioworks as of Q3 2024.

Based on Lazard Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.